Compare Biogen Inc (BIIB) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs ServiceNow Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while ServiceNow Inc trades at $106.18 (market cap $108.13B). The key difference: ServiceNow Inc is far larger — about 3.8× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | NOW | |
|---|---|---|
Market Cap | $28.34B | $108.13B |
Sector | Health | Technology |
52-Week High | $216.63 | $199.24 |
52-Week Low | $122.68 | $83.00 |
Enterprise Value | $30.62B | $105.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
ServiceNow (NOW) trades at $104.85, down 2.66% on the day, amid a generally bullish technical and fundamental backdrop. The stock exhibits strong revenue growth, with 2025 revenue reaching $13.28B and a robust net income margin of 12.59%. Analyst sentiment is overwhelmingly positive, with an 85.51% buy rating and a consensus price target of $137.96, suggesting significant upside potential. Recent news highlights the company's positioning as an 'AI control tower,' with strong performance in May.
The outlook for NOW is favorable, driven by AI adoption and consistent earnings beats, though high valuation multiples (P/E of 66.23) pose a risk if growth slows. Key investment opportunities include expanding profit margins and market share in enterprise software, while risks involve competitive pressures and execution challenges in a high-interest-rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
